Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Bosutinib in patients with Chronic Myelogenous Leukemia.

Statements

Source and description
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.
Bosulif (bosutinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.
Bosulif (bosutinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult patients with accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.